BioRestorative Therapies Inc
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The company's products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected fro… Read more
BioRestorative Therapies Inc (BRTX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -1.315x
Based on the latest financial reports, BioRestorative Therapies Inc (BRTX) has a cash flow conversion efficiency ratio of -1.315x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.90 Million) by net assets ($2.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
BioRestorative Therapies Inc - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how BioRestorative Therapies Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
BioRestorative Therapies Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioRestorative Therapies Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ICNP
PINK:ICNP
|
0.201x |
|
STEEL DYNAMICS - Dusseldorf Stock Exchang
DU:SD5
|
0.084x |
|
PT BK PANIN DU. SY. RP100
F:2PS
|
N/A |
|
Pure Foods Tasmania Ltd
AU:PFT
|
-0.073x |
|
BSF Enterprise Plc
PINK:BSFAF
|
-0.092x |
|
Mystic Holdings Inc.
OTCQB:MSTH
|
N/A |
|
C.H.ROBINSON WLDWDE - Dusseldorf Stock Exchang
DU:CH1A
|
0.066x |
|
Orphazyme A/S
PINK:OZYMF
|
0.000x |
Annual Cash Flow Conversion Efficiency for BioRestorative Therapies Inc (2010–2024)
The table below shows the annual cash flow conversion efficiency of BioRestorative Therapies Inc from 2010 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $8.53 Million | $-8.23 Million | -0.965x | -50.09% |
| 2023-12-31 | $10.00 Million | $-6.43 Million | -0.643x | -11.85% |
| 2022-12-31 | $10.29 Million | $-5.91 Million | -0.575x | -272.69% |
| 2021-12-31 | $21.60 Million | $-3.33 Million | -0.154x | -110.45% |
| 2020-12-31 | $-1.33 Million | $-1.96 Million | 1.475x | +172.42% |
| 2019-12-31 | $-12.78 Million | $-6.92 Million | 0.542x | -8.33% |
| 2018-12-31 | $-8.64 Million | $-5.10 Million | 0.591x | +4.80% |
| 2017-12-31 | $-6.84 Million | $-3.85 Million | 0.564x | -43.66% |
| 2016-12-31 | $-5.00 Million | $-5.00 Million | 1.000x | +25.25% |
| 2015-12-31 | $-3.91 Million | $-3.12 Million | 0.799x | +70.47% |
| 2014-12-31 | $-6.89 Million | $-3.23 Million | 0.469x | +17.22% |
| 2013-12-31 | $-6.69 Million | $-2.67 Million | 0.400x | -35.45% |
| 2012-12-31 | $-5.14 Million | $-3.18 Million | 0.619x | -18.78% |
| 2011-12-31 | $-3.69 Million | $-2.81 Million | 0.762x | -22.18% |
| 2010-12-31 | $-744.22K | $-729.22K | 0.980x | -- |